Рекомендации Российской гастроэнтерологической ассоциации по лечению болезни Крона у взрослых (проект)

1. Адлер Г. Болезнь Крона и язвенный колит. – М.: Изд. дом «Гэотар-МЕД», 2001. – С. 26, 348, 355–358.

2. Голованчикова В.М., Шифрин О.С., Ивашкин В.Т. Современные подходы к лечению хронических воспалительных заболеваний кишечника // Рос. мед. вести. – 2009. – Т. 14, № 3. – С. 29–37.

3. Ивашкин В.Т. Рациональная фармакотерапия заболеваний органов пищеварения: Руководство для практикующих врачей / Под общей ред. В.Т. Ивашкина. – М.: Литература, 2003. –Т. 4. – С. 499–521.

4. Соколина И.А., Леонович А.Е., Шифрин О.С., Шехтер А.В. Компьютерно-томографическая семиотика клинических форм болезни Крона. Невский радиологический форум «Новые горизонты»: Сб. науч. трудов. – СПб, 2007. – С. 224–225.

5. Шифрин О.С. Болезнь Крона: особенности патогенеза, клиники и лечения // Consilium medicum. – 2001. – Т. 3, № 6. – С. 261–266.

6. Шифрин О.С. Римикейд – новый этап в лечении воспалительных заболеваний кишечника // Consilium medicum. – 2005. – T. 3, № 1 (приложение).

7. Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther. 2005; 15 (21):307–19.

8. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005:CD003715.

9. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005:CD003459.

10. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005; 34 (5, suppl. 1):19–22.

11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term eicacy of infliximab in Crohn’s disease. N Engl J Med. 2003; 13 (348):601–8.

12. Best W, Becktel J, Singleton, et al. Development of a Crohn’s disease activity index. National Cooperation Crohn’s Disease Study. Gastroenterology. 1976; 70:439–44.

13. Borgaonkar M, MacIntosh D, Fardy J, et al. Antituberculous therapy for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000:CD000299.

14. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997; 113(5):1465-73.

15. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006. 55 (suppl. 1):36–58.

16. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003. 98:1315–24.

17. Cheifetz AS, Kornbluth AA, Legnani P, et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn’s disease. Am J Gastroenterol. 2006. 101. P. 2218–22.

18. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther. 2001. 15:35–44;

19. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118:1025–30.

20. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM Trial. Gastroenterology. 2007; 132:52–65.

21. Connell WR, Kamm MA, Dickson M, et al. Longterm neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994; 343:1249–52.

22. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993; 34:1081–5.

23. Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut. 2001; 48:186–90.

24. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn’s disease. Am J Gastroenterol. 2005; 100:2225–9.

25. Cuffari C, Dubinsky M, Darbari A, et al. Crohn’s jejunoileitis: the pediatrician’s perspective on diagnosis and management. Inflamm Bowel Dis. 2005; 11:696–704.

26. Desmond AN, O’Regan K, Curran C, et al. Crohn’s disease: factors associated with exposure to high levels of diagnostic radiation. Gut. 2008; 57:1524–9.

27. Dietrich CF. Significance of abdominal ultrasound in inflammatory bowel disease. Dig Dis. 2009; 27:482–93.

28. Dignass A, van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010; 4 (1):28–62.

29. Dubinsky MC, Reyes E, Ofman J, et al. A costeffectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100:2239–47.

30. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122:904–15.

31. Edwards JT, Radford-Smith GL, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001; 16:1235–8.

32. Egan LI, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and istulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol. 1998; 93:442–8.

33. Eliakim R, Suissa A, Yassin K, et al. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn’s disease – final report. Dig Liver Dis. 2004; 36:519–22.

34. Ewe K, Herfarth C, Malchow H, et al. Postoperative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion. 1989; 42:224–32.

35. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003; 124:917–24.

36. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121:255–60.

37. Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996; 224:563–71; discussion 71–3.

38. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 2000; 342:1627–32.

39. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995; 332:292–7.

40. Felder JB, Adler DJ, Korelitz BI. The safety of corticosteroid therapy in Crohn’s disease with an abdominal mass. Am J Gastroenterol. 1991; 86:1450–5.

41. Fellermann K, Ludwig D, Stahl M, et al. Steroidunresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998; 93:1860–6.

42. Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn’s disease – results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther. 1998; 12:175–83.

43. Franchimont DP, Louis E, Croes F, et al. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol. 1998; 10:821–5.

44. Freeman HJ. Long-term clinical behavior of jejunoileal involvement in Crohn’s disease. Can J Gastroenterol. 2005; 19:575–8.

45. Gardiner KR, Dasari BV. Operative management of small bowel Crohn’s disease. Surg Clin North Am. 2007; 87:587–610.

46. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000; 6:8–15.

47. Geboes K, Rutgeerts R, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin. 2005; 21:1741–54.

48. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study, Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996; 110:45–51.

49. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol. 2008; 81:362–78.

50. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–9.

51. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004; 127:723–9.

52. Hanauer SB, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn’s disease: a placebocontrolled trial. Aliment Pharmacol Ther. 2005; 21:363–71.

53. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn´s disease: The Classic-I Trial. Gastroenterology. 2006; 130:323–332.

54. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004; 2:379–88.

55. Hanauer SB, Wagner CL, Bala M. et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004; 2:542–53.

56. Hassan C, Zullo A, de Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007; 26:1457–64.

57. Hogezand RA, Witte AM, Veenendaal RA, et al. Proximal Crohn’s disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis. 2001; 7:328–37.

58. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am. 2004; 33:335–45.

59. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1432–42.

60. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984; 79:533–40.

61. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004; 19:287–93.

62. Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2011; 34 (3):306–17.

63. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54:1121–5.

64. Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther. 2002; 16:1509–17.

65. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med. 2001; 345:1098–104

66. Kornbluth A, Marion JF, Salomon P, et al. How effective is current medical therapy for severe ulcerative and Crohn’s colitis? An analytic review of selected trials. J Clin Gastroenterol. 1995; 20:280–4.

67. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998; 114:1151–60.

68. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128:1812–8.

69. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006; 130:1054–61.

70. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000; 95:1730–4.

71. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000; 118:1018–24.

72. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130:935–94.

73. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009; 104(2):465–83.

74. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004; 99:91–6.

75. Loberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo-controlled one year study. Gut. 1996; 39:82–6.

76. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology. 2000; 118:264–73.

77. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504–17.

78. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994; 39:1193–6.

79. Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn’s disease: a case series. Aliment Pharmacol Ther. 2003; 18:1003–8.

80. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984; 86:249–66.

81. Markowitz J, Markowitz JE, Bousvaros A, et al. Workshop report: prevention of postoperative recurrence in Crohn’s disease. J Pediatr Gastroenterol Nutr. 2005; 41:145–51.

82. McDonald J, Feagan B, Jewell D, et al. Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2005; 18; (2):CD000297.

83. McLeod RS. Surgery for inflammatory bowel diseases. Dig Dis. 2003; 21:168–7.

84. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Gastroenterology. 1990; 98:811–8.

85. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995; 30:699–706.

86. Nancey S, Blanvillain E, Parmentier B, et al. Infliximab treatment does not induce organ-specific or nonorganspecific autoantibodies other than antinuclear and antidouble-stranded DNA autoantibodies in Crohn’s disease. Inflamm Bowel Dis. 2005; 11:986–91.

87. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103:1443–50.

88. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thiogua-nine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130:1047–53.

89. Osterman MT, Lichtenstein GR. Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options Gastroenter. 2007; 10:195–207.

90. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2005:CD000296.

91. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000:CD000067.

92. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417–29.

93. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006; 23:1117–25.

94. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999; 340:1398–405.

95. Regueiro MMD, Schraut WMDP, Baidoo LMD, et al. Infliximab for prevention of Crohn’s Disease (CD) recurrence ater ileal resection. Am J Gastroenterol. 2008; 103 (suppl.):412.

96. Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther. 2005; 21:829–39.

97. Rutgeerts P, Diamond RH, Bal. a M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006; 63:433–42.

98. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004; 126:402–13.

99. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990; 99:956.

100. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence ater ileal resection. Gastroenterology. 1995; 108:1617–21.

101. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994; 331:842–5.

102. Rutgeerts P, van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebocontrolled trial. Gastroenterology. 2005; 128:856–61.

103. Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004; 126:1593–610.

104. Rutgeerts P. An historical overview of the treatment of Crohn’s disease: why do we need biological therapies? Rev Gastroenterol Disord. 2004; 4 (suppl. 3): S3–9.

105. Rutgeerts P. Review article: treatment of perianal istulizing Crohn’s disease. Aliment Pharmacol Ther. 2004; 20 (suppl. 4):106–10.

106. Sackett DL, Strauss SE, Richardson WS, et al. Evidence-Based Medicine: How to Practice and Teach EBM. Philadelphia, Pa: Churchill-Livingstone; 2000.

107. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003; 125:1508–30.

108. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007; 357:228–38.

109. Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn’s disease remains uncertain. Gastroenterology. 2004; 127:990–3.

110. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007; 56:1232–9.

111. Sandborn WJ, Loberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005; 100:1780–7.

112. Sandborn WJ, Rogler G. The keys to IBD 2010: Treatment, diagnosis and pathophysiology. Peprint of Dogestive Disease. 2010; 28 (3).

113. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146:829–38.

114. Sandborn WJ, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2000:CD000545.

115. Sandborn WJ, Rutgeerts PM, Reinisch WM, et al. Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. Am J Gastroenterol. 2008; 103 (suppl.):436.

116. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for istulizing Crohn’s disease. N Engl J Med. 2004; 350:876–85.

117. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004; 126:1518–32.

118. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007; 357:239–50.

119. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005; 129:807–18.

120. Schroder O, Blumenstein I, Schulte-Bockholt A, et al. Combining infliximab and methotrexate in istulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004; 19:295–301.

121. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin and clofazimine for Crohn’s disease. Gastroenterology. 2007; 132:2313–9.

122. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn’s disease. Curr Med Res Opin. 2005; 21:1165–9.

123. Siegel CA, Hur C, Korzenik JR, et al. Risks and beneits of infliximab for the treatment of Crohn’s disease. Clin Gastroenterol Hepatol. 2006; 4:1017–24.

124. Silverstein MD, Lofus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999; 117(1):49–57.

125. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2001:CD002913.

126. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in auto-immunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006; 15:2069–77.

127. Spada C, Riccioni ME, Costamagna G. Patients with known small bowel stricture or with symptoms of small bowel obstruction secondary to Crohn’s disease should not perform video capsule endoscopy without being previously tested for small bowel patency. Am J Gastroenterol. 2007; 102:1542–3.

128. Spada C, Shah SK, Riccioni ME, et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol. 2007; 41:576–82.

129. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and manage ment of Crohn’s disease: definitions and diagnosis. Gut. 2006; 55 (suppl. 1):11–15.

130. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979; 77:847–69.

131. Swan NC, Geoghegan JG, O’Donoghue DP, et al. Fulminant colitis in inflammatory bowel disease: detailed pathologic and clinical analysis. Dis Colon Rectum. 1998; 41:1511–5.

132. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease, Crohn’s Disease cA2 Study Group. N Engl J Med. 1997; 337:1029–35.

133. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000; 95:3150–6.

134. Thirlby RC, Land JC, Fenster LF, et al. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg. 1998; 133:826–32.

135. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease

136. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998; 339:370–4.

137. Tilney HS, Constantinides VA, Heriot AG, et al. Comparison of laparoscopic and open ileocecal resection for Crohn’s disease: a meta-analysis. Surg Endosc. 2006; 20:1036–445.

138. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006; 55 (suppl. 1):16–35.

139. Tremaine WJ. Gastroduodenal Crohn’s disease: medical management. Inflamm Bowel Dis. 2003; 9:127–8.

140. Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol. 2006; 22:370–6.

141. Vandeputte L, Haens G, Baert F, et al. Methotrexate in refractory Crohn’s disease. Inflamm Bowel Dis. 1999; 5:11–5.

142. Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease. J Gastroenterol. 2004; 39:441–8.

143. Zachos M, Tondeur M, Griiths AM. Enteral nutritional therapy for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2001:CD000542.